IART vs RCEL
IART: A global medical technology leader specializing in neurosurgery and regenerative tissue reconstruction. RCEL: AVITA Medical provides regenerative, point-of-care cell harvesting technology and wound management solutions to transform acute wound care.
Side-by-side fundamentals
| Metric | IART | RCEL | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $13.33 | $13.80 | |
| Market cap | $1.0B | $427M | |
| Net margin FY2025, SEC XBRL | -31.6% | -67.8% | IART higher |
| Gross margin FY2025, SEC XBRL | n/a | +82.1% | |
| Operating margin FY2025, SEC XBRL | -30.2% | -59.4% | IART higher |
| ROE FY2025, SEC XBRL | -49.5% | n/a | |
| ROA FY2025, SEC XBRL | -14.3% | -86.2% | IART higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.68 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +1.5% | +11.4% | RCEL higher |
| Revenue CAGR (3y) SEC XBRL | +1.6% | +27.7% | RCEL higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.40 | 1.36 | |
| 1-year return as of 2026-10-20 close | -15.0% | +244.1% | RCEL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.